Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2008

01-10-2008 | Gastrointestinal Oncology

CD133+CD44+ Population Efficiently Enriches Colon Cancer Initiating Cells

Authors: Naotsugu Haraguchi, MD, PhD, Masahisa Ohkuma, MD, Hiroyuki Sakashita, MD, Shinji Matsuzaki, MD, Fumiaki Tanaka, MD, PhD, Koshi Mimori, MD, PhD, Yukio Kamohara, MD, PhD, Hiroshi Inoue, MD, PhD, Masaki Mori, MD, PhD

Published in: Annals of Surgical Oncology | Issue 10/2008

Login to get access

Abstract

Background

Previous reports have demonstrated that CD133+ cells or CD44+ cells might be cancer initiating cells (CIC) of colon cancer. However, the association between the two cell types is unclear. In this study, we evaluated the tumorigenicity of each population of human colon cancer divided by CD133 and CD44 using non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice.

Methods

Using the colon cancer cell lines HT29 and Caco2 we evaluated the change of expression status of CD133 or CD44 by a treatment with sodium butyrate (NaBT) that can induce cellular differentiation. Next, we prepared ten clinical samples of colon cancer and analyzed the expression and tumorigenicity of CD133 and CD44.

Results

With NaBT treatment, CD44 expression was greatly downregulated in both HT29 and Caco2 (HT29: nontreatment versus treatment; 77.8% versus 0.6%, Caco2: 14.0% versus 0.4%, respectively), more than CD133 expression (HT29: nontreatment versus treatment; 90.1% versus 67.7%, Caco2: 98.9% versus 76.3%, respectively). In clinical samples, the percentages of CD133+ cells and CD44+ cells varied from 0.3% to 82.0% (mean 35.5%), and from 11.5% to 58.4% (mean 30.0%), respectively. Subcutaneous injection of CD133+ or CD44+ cells made a tumor in all mice (3/3 and 4/4, respectively). The combined analysis of CD133 and CD44 revealed that only the CD133+CD44+ population had the ability to produce a tumor (3/3).

Conclusion

The findings demonstrate that, at present, the CD133+CD44+ population may be the best to identify tumor initiating cells of human colon cancer.
Literature
1.
Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645–8PubMedCrossRef
2.
Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004;101:781–6PubMedCrossRef
3.
Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396–401PubMedCrossRef
4.
Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983–8PubMedCrossRef
5.
Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005;121:823–35PubMedCrossRef
6.
Wang S, Garcia AJ, Wu M, et al. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci USA 2006;103:1480–5PubMedCrossRef
7.
Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003;3:895–902PubMedCrossRef
8.
Ieta K, Tanaka F, Haraguchi N, et al. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 2007;15:638–48PubMedCrossRef
9.
O’Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106–10PubMedCrossRef
10.
Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111–5PubMedCrossRef
11.
Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007;104:10158–63PubMedCrossRef
12.
Augeron C, Laboisse CL. Emergence of permanently differentiated cell clones in a human colonic cancer cell line in culture after treatment with sodium butyrate. Cancer Res 1984;44:3961–9PubMed
13.
Sussman NL, Eliakim R, Rubin D, et al. Intestinal alkaline phosphatase is secreted bidirectionally from villous enterocytes. Am J Physiol 1989;257:G14–23PubMed
14.
Souleimani A, Asselin C. Regulation of c-myc expression by sodium butyrate in the colon carcinoma cell line Caco-2. FEBS Lett 1993;326:45–50PubMedCrossRef
15.
Tsutsumi T, Ido A, Nakao K, et al. Reciprocal regulation of alpha-fetoprotein and albumin gene expression by butyrate in human hepatoma cells. Gastroenterology 1994;107:499–504PubMed
16.
Graham KA, Buick RN. Sodium butyrate induces differentiation in breast cancer cell lines expressing the estrogen receptor. J Cell Physiol 1988;136:63–71PubMedCrossRef
17.
El-Deriny SE, O’Brien MJ, Christensen TG, et al. Ultrastructural differentiation and CEA expression of butyrate-treated human pancreatic carcinoma cells. Pancreas 1987;2:25–33PubMedCrossRef
Metadata
Title
CD133+CD44+ Population Efficiently Enriches Colon Cancer Initiating Cells
Authors
Naotsugu Haraguchi, MD, PhD
Masahisa Ohkuma, MD
Hiroyuki Sakashita, MD
Shinji Matsuzaki, MD
Fumiaki Tanaka, MD, PhD
Koshi Mimori, MD, PhD
Yukio Kamohara, MD, PhD
Hiroshi Inoue, MD, PhD
Masaki Mori, MD, PhD
Publication date
01-10-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0074-0

Other articles of this Issue 10/2008

Annals of Surgical Oncology 10/2008 Go to the issue

Hepatic and Pancreatic Tumors

Surgical Management of Hepatocellular Adenoma: Take It or Leave It?

Thoracic Oncology

Refining Esophageal Cancer Staging After Neoadjuvant Therapy: Importance of Treatment Response

Gastrointestinal Oncology

Sentinel Node Biopsy Without Scars

Bone and Soft Tissue Sarcomas

Isolated Limb Infusion for Advanced Soft Tissue Sarcoma of the Extremity

Breast Oncology

Axillary Surgery in DCIS: Is Less More?

Bone and Soft Tissue Sarcomas

A Large-Scale Study of MT1–MMP as a Marker for Isolated Tumor Cells in Peripheral Blood and Bone Marrow in Gastric Cancer Cases